Hauke, Ralph

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Powles, T., Csőszi, T., Özgüroğlu, M., Matsubara, N., Géczi, L., Cheng, S. Y.-S., Fradet, Y., Oudard, S., Vulsteke, C., Morales Barrera, R., et al. (2021) · The Lancet Oncology

Bladder and Urothelial Cancer TreatmentsCancer Immunotherapy and Biomarkers

Cited by 643

Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer

Chi, K. N., Rathkopf, D., Smith, M. R., Efstathiou, E., Attard, G., Olmos, D., Lee, J. Y., Small, E. J., Pereira de Santana Gomes, A. J., Roubaud, G., et al. (2023) · Journal of Clinical Oncology

Prostate Cancer Treatment and ResearchPARP inhibition in cancer therapy

Cited by 355

Developing a Service Model That Integrates Palliative Care Throughout Cancer Care: The Time Is Now

Partridge, A. H., Seah, D. S. E., King, T., Leighl, N. B., Hauke, R., Wollins, D. S., & Von Roenn, J. H. (2014) · Journal of Clinical Oncology

Palliative Care and End-of-Life IssuesPalliative and Oncologic Care

Cited by 91

ARC-20: a Phase 1 dose-escalation and dose-expansion study to investigate the safety, tolerability, and pharmacology of HIF-2α inhibitor AB521 monotherapy in patients with clear cell renal cell carcinoma and other solid tumors

Choueiri, T. K., Garmezy, B., Paterson, E., Ghasemi, M., Cheng, T., Foster, P. G., Hauke, R. J., & Patnaik, A. (2023) · Journal of Clinical Oncology

Renal cell carcinoma treatmentCancer, Hypoxia, and Metabolism

Cited by 5

A Phase 1/2, open label dose-escalation and expansion trial of NKT2152, an orally administered HIF2α inhibitor, to investigate safety, PK, PD and clinical activity in patients with advanced ccRCC

Jonasch, E., Hauke, R., Falchook, G., Logan, T., Gordon, M., Hall, E., Schuch, B., Bilen, M. A., Naqash, A., Zakaharia, Y., et al. (2023) · The Oncologist

Renal cell carcinoma treatmentCancer, Hypoxia, and Metabolism

Cited by 1